Ilan Ganot, Solid Bio CEO (Solid Bio)
Solid Bio’s long, troubled slog through the clinic yields 'encouraging' early data and no new safety concerns. It's not winning over investors yet
Those who have been following the gene therapy space would be familiar with Solid Bio’s IGNITE-DMD trial. Beset with safety issues, the Phase I/II study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
